Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans
Abstract Introduction Ulotaront (SEP-363856), a dual trace animeassociated receptor 1 (TAAR1) and 5-HT1A receptor agonist, is in phase 3 clinical development for the treatment of schizophrenia. This study evaluated the comparative bioequivalence (BE) between tablet and capsule formulations of ulotar...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2023-03-01
|
Series: | Neurology and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s40120-023-00459-8 |